Dataset Information

Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review.

ABSTRACT:

Background

Decision impact studies have become increasingly prevalent in cancer prognostic research in recent years. These studies aim to evaluate the impact of a genomic test on decision-making and appear to be a new form of evidence of clinical utility. The objectives of this review were to identify and characterize decision impact studies in genomic medicine in cancer care and categorize the types of clinical utility outcomes reported.

Methods

We conducted a search of four databases, Medline, Embase, Scopus and Web of Science, from inception to June 2022. Empirical studies that reported a "decision impact" assessment of a genomic assay on treatment decisions or recommendations for cancer patients were included. We followed scoping review methodology and adapted the Fryback and Thornbury Model to collect and analyze data on clinical utility. The database searches identified 1803 unique articles for title/abstract screening; 269 articles moved to full-text review.

Results

87 studies met inclusion criteria. All studies were published in the last 12 years with the majority for breast cancer (72%); followed by other cancers (28%) (lung, prostate, colon). Studies reported on the impact of 19 different proprietary (18) and generic (1) assays. Across all four levels of clinical utility, outcomes were reported for 22 discrete measures, including the impact on provider/team decision-making (100%), provider confidence (31%); change in treatment received (46%); patient psychological impacts (17%); and costing or savings impacts (21%). Based on the data synthesis, we created a comprehensive table of outcomes reported for clinical utility.

Conclusions

This scoping review is a first step in understanding the evolution and uses of decision impact studies and their influence on the integration of emerging genomic technologies in cancer care. The results imply that DIS are positioned to provide evidence of clinical utility and impact clinical practice and reimbursement decision-making in cancer care. Systematic review registration: Open Science Framework osf.io/hm3jr.

SUBMITTER: Parker G

PROVIDER: S-EPMC10004522 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review.

Parker Gillian G Hunter Sarah S Ghazi Samer S Hayeems Robin Z RZ Rousseau Francois F Miller Fiona A FA

PloS one 20230310 3

<h4>Background</h4>Decision impact studies have become increasingly prevalent in cancer prognostic research in recent years. These studies aim to evaluate the impact of a genomic test on decision-making and appear to be a new form of evidence of clinical utility. The objectives of this review were to identify and characterize decision impact studies in genomic medicine in cancer care and categorize the types of clinical utility outcomes reported.<h4>Methods</h4>We conducted a search of four data ...[more]

PMID: 36897859

Similar Datasets

Project description:BackgroundInvestigating the causes of stillbirth is crucial for both parents and healthcare providers as it helps explain why the baby died, guides clinical care in future pregnancies, and aids in developing strategies to prevent stillbirth. The usefulness or utility of investigations for stillbirth is poorly defined and unclear. As a result, protocols for investigating the causes of stillbirth are currently based on clinical consensus and fail to prioritise investigative approaches that are most effective at determining a cause of death.ObjectivesThe objectives of this scoping review were to identify the available evidence, key characteristics, and knowledge gaps regarding the utility of stillbirth investigations.Search strategyAn a priori protocol was implemented and included a systematic search in MEDLINE, CINAHL, EMBASE, Scopus, and Cochrane from inception until 28 May 2024.Selection criteriaStudies examining stillbirth investigations, yield, and value were included.Data collection and analysisData were collected using a purpose-built data extraction tool and an analysis was undertaken.Results57 potentially eligible studies were identified, and 34 studies (with 11,410 stillbirths) were included. Three studies examined clinical utility using a comprehensive testing protocol. Definition of utility or value of investigations varied across the studies, classification system for cause of death and investigation protocols varied. Placental pathology was reported as the most useful investigation in 65%-96% of cases, identified a cause of death in 61-71% of cases and impacting the medical management in 36% of cases (13 studies, 5,169 stillbirths). Autopsy can identify the cause of death in 36-77% of cases and provided new information in 17-26% of cases (17 studies, 4,336 stillbirths). Genetic analysis was useful in 29% of cases (seven studies, 1,886 stillbirths). One study (512 stillbirths) examined the value of investigation by presenting clinical scenario.ConclusionsThis review indicates that Investigation protocols for stillbirth should include placental pathology, autopsy, and genetic testing. Future studies should address the value of tests by presenting clinical scenarios, use of a consistent definition of stillbirth, classification system and measurement of investigation value.

Project description:BackgroundThe health care industry must align with new digital technologies to respond to existing and new challenges. Digital twins (DTs) are an emerging technology for digital transformation and applied intelligence that is rapidly attracting attention. DTs are virtual representations of products, systems, or processes that interact bidirectionally in real time with their actual counterparts. Although DTs have diverse applications from personalized care to treatment optimization, misconceptions persist regarding their definition and the extent of their implementation within health systems.ObjectiveThis study aimed to review DT applications in health care, particularly for clinical decision-making (CDM) and operational decision-making (ODM). It provides a definition and framework for DTs by exploring their unique elements and characteristics. Then, it assesses the current advances and extent of DT applications to support CDM and ODM using the defined DT characteristics.MethodsWe conducted a scoping review following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) protocol. We searched multiple databases, including PubMed, MEDLINE, and Scopus, for original research articles describing DT technologies applied to CDM and ODM in health systems. Papers proposing only ideas or frameworks or describing DT capabilities without experimental data were excluded. We collated several available types of information, for example, DT characteristics, the environment that DTs were tested within, and the main underlying method, and used descriptive statistics to analyze the synthesized data.ResultsOut of 5537 relevant papers, 1.55% (86/5537) met the predefined inclusion criteria, all published after 2017. The majority focused on CDM (75/86, 87%). Mathematical modeling (24/86, 28%) and simulation techniques (17/86, 20%) were the most frequently used methods. Using International Classification of Diseases, 10th Revision coding, we identified 3 key areas of DT applications as follows: factors influencing diseases of the circulatory system (14/86, 16%); health status and contact with health services (12/86, 14%); and endocrine, nutritional, and metabolic diseases (10/86, 12%). Only 16 (19%) of 86 studies tested the developed system in a real environment, while the remainder were evaluated in simulated settings. Assessing the studies against defined DT characteristics reveals that the developed systems have yet to materialize the full capabilities of DTs.ConclusionsThis study provides a comprehensive review of DT applications in health care, focusing on CDM and ODM. A key contribution is the development of a framework that defines important elements and characteristics of DTs in the context of related literature. The DT applications studied in this paper reveal encouraging results that allow us to envision that, in the near future, they will play an important role not only in the diagnosis and prevention of diseases but also in other areas, such as efficient clinical trial design, as well as personalized and optimized treatments.

Project description:BackgroundSpinal disorders are highly prevalent worldwide with high socioeconomic costs. This cost is associated with the demand for treatment and productivity loss, prompting the exploration of technologies to improve patient outcomes. Clinical decision support systems (CDSSs) are computerized systems that are increasingly used to facilitate safe and efficient health care. Their applications range in depth and can be found across health care specialties.ObjectiveThis scoping review aims to explore the use of CDSSs in patients with spinal disorders.MethodsWe used the Joanna Briggs Institute methodological guidance for this scoping review and reported according to the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) statement. Databases, including PubMed, Embase, Cochrane, CINAHL, Web of Science, Scopus, ProQuest, and PsycINFO, were searched from inception until October 11, 2022. The included studies examined the use of digitalized CDSSs in patients with spinal disorders.ResultsA total of 4 major CDSS functions were identified from 31 studies: preventing unnecessary imaging (n=8, 26%), aiding diagnosis (n=6, 19%), aiding prognosis (n=11, 35%), and recommending treatment options (n=6, 20%). Most studies used the knowledge-based system. Logistic regression was the most commonly used method, followed by decision tree algorithms. The use of CDSSs to aid in the management of spinal disorders was generally accepted over the threat to physicians' clinical decision-making autonomy.ConclusionsAlthough the effectiveness was frequently evaluated by examining the agreement between the decisions made by the CDSSs and the health care providers, comparing the CDSS recommendations with actual clinical outcomes would be preferable. In addition, future studies on CDSS development should focus on system integration, considering end user's needs and preferences, and external validation and impact studies to assess effectiveness and generalizability.Trial registrationOSF Registries osf.io/dyz3f; https://osf.io/dyz3f.

Dataset Information

Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review.

Background

Methods

Results

Conclusions

Publications

Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets